Clinical research study for the treatment of Brain Cancer in teenagers and adults at Levine Cancer Institute

Patients are needed to participate in a clinical research study evaluating Nivolumab, Temozolomide and Radiotherapy for the treatment of Brain Cancer.
A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)

Purpose:The main purpose of this study is to compare how long patients with glioblastoma (GBM, a malignant brain cancer) live after receiving nivolumab every two weeks in addition to radiation therapy (RT), and then every four weeks, compared with patients receiving standard therapy with temozolomide in addition to RT.

Gender:
Both Male and Female.
Age:
18 and up.